alexa Does Methylphenidate (MPD) Have the Potential to Become Drug of Abuse? | Open Access Journals
ISSN: 2167-0501
Biochemistry & Pharmacology: Open Access
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Does Methylphenidate (MPD) Have the Potential to Become Drug of Abuse?

Nachum Dafny*
University of Texas Health Science Center Medical School at Houston, Texas, USA
Corresponding Author : Nachum Dafny
University of Texas Health Science Center Medical School at Houston 6431 Fannin St. MSB 7.208B
Houston, Texas 77030, USA
Tel: 713-500-5616
Fax: 713-500-0621
E-mail: [email protected]
Received October 29, 2014; Accepted December 17, 2014; Published December 24, 2014
Citation: Dafny N (2014) Does Methylphenidate (MPD) Have the Potential to Become Drug of Abuse?. Biochem Pharmacol (Los Angel) 4:156. doi:10.4172/2167-0501.1000156
Copyright: © 2014 Dafny N et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Biochemistry & Pharmacology: Open Access

Abstract

The psychostimulant methylphenidate (MPD) is the pharmacotherapy of choice for the treatment of attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), narcolepsy, dementia, chronic fatigue and useful in providing relief from intractable pain. More recently students of all ages use MPD (Ritalin) as a cognitive enhancement to help them study and perform better during exams. Many of them abuse the drug for recreation. This chapter aims to provide a short review of the pharmacological property of MPD. MPD can elicit behavioral sensitization or tolerance – behavioral sensitization and tolerance are experimental markers indicating dependence. Some behavior experiments using an MPD dose response protocol demonstrated that MPD elicits behavioral sensitization and other studies reported behavioral tolerance. Our dose response study of chronic MPD dose response experiment demonstrated that the same dose of MPD in some animals elicited behavioral sensitization and in others animals behavioral tolerance.

Keywords
Methylphenidate; Ritalin; Behavioral sensitization; Behavioral tolerance; Neurotransmitters; Neurodevelopmental; Acute; Chronic
Introduction
The psychostimulant methylphenidate is the first line of pharmacotherapy treatment for attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), narcolepsy, memoryimpairment (dementia) in older individuals, and chronic fatigue [1]. Psychostimlant medication such as amphetamine was used to treat ADD and ADHD patients from the 1930’s until it was found that it elicited dependence. The psychostimulant methylphenidate has since become the drug of choice for ADD and ADHD patients [2].
Methylphenidate (MPD) is used by children and young adults during their developmental stages where overproduction and synaptic pruning in the central nervous system (CNS) occurs which may have an effect on the developing brain. Youth are striking deals to buy and sell MPD (Ritalin) to improve their brain functions and for recreation, while the number of fatalities associated with its misuse has risen to record levels. MPD has similar rapid uptake in the brain to that of cocaine and amphetamine, but differs from them by having a much lower rate of clearance from the brain. Intravenous (i.v.) or intranasal administration of MPD has a higher mortality rate than cocaine or amphetamine [3].
Pharmacological property of Methylphenidate (MPD)
MPD is administered as a racemic mixture of the d-and l-threoenantiomers; however, the d-enantiomer is thought to be the primary responsible for its therapeutic effects. When MPD is given orally, it is absorbed from the intestinal tract and has a half- life of about 1 hour with equally short duration and efficacy. The dose and route of MPD administration are important because the features of the behavioral and neurochemical responses to the drug are dependent on the speed of the drug to reach peak level, i.e. the rise time of the drug concentration. Peak levels of MPD following intravenous (i.v.), intraperitoneal (i.p), and oral administration was 8-20 min, 15-28 min, and 60-90 min, respectively [4,5]. Similar peak levels of i.v., i.p., and oral administrations were obtained following amphetamine and cocaine [4]. The ability to reach peak levels in short spans of time (i.e. 8-30 min) is one of the main factors in eliciting adverse effects such as sensitization. MPD given systematically binds with similar affinity at the dopamine transporter (DAT) and has potency (Ki=200) similar to cocaine (Ki=224) [5]. The relationship between drug doses (milligrams of hydrochloride salt/kilograms of body weight) and percentage occupancy of DAT is identical for cocaine and MPD in rodents and humans [6]. MPD is absorbed and metabolized via deetherification to ritalinic acid and released into the urine within 48 hours. Brain concentration of MPD exceeds that of plasma since the psychostimulants are concentrated in catecholaminergic systems with free passage across the blood brain barrier. MPD has a similar uptake in the brain as cocaine, but differs from cocaine by having a much lower rate of clearance from the brain. The outcome of MPD treatment results primarily in preventing the reuptake of dopamine (DA), norepinephrine (NE), and serotonin (5HT) from the synaptic cleft to the presynaptic terminals. Like cocaine, MPD is an indirect catecholamine (CA) agonist since it does not stimulate the catecholaminergic receptors directly, but rather facilitates the action of the CA [6,7]. The therapeutic effect of MPD in the treatment of ADHD has been attributed to its ability to increase the efflux of these neurotransmitters. This causes increases in extracellular DA, NA, and 5HT levels [5], which have an effect that has been linked to its reinforcing properties. MPD has moderate effects on the peripheral circulatory system. In rats, acute MPD administration in low doses (1-3 mg/kg) stimulates locomotor activity, and in high doses (10 mg/kg and higher) further increases in locomotion occur, and it also stimulates stereotypical behavior [8,9]. Following its repetitive (chronic) use it can elicit either behavioral tolerance or behavioral sensitization [10-12].
Behavioral tolerance is defined by the following criterion: repetitive exposure with the same dose of MPD will become less effective to elicit its initial effects. Behavioral sensitization is defined as reverse tolerance, i.e. repetitive exposure with the same MPD dose will elicit a significant further increase in its behavioral effects compared to that elicited by the initial (acute) dose. Behavioral sensitization and/or tolerance is considered a long lasting neuroplasticity elicited following repetitive psychostimulant exposure. It has been suggested that behavioral tolerance and sensitization represent an enduring alteration of drug response and have been used as an experimental model of drug craving [13].
Does MPD elicit tolerance or sensitization?
One of the most used assays to study animal behavior is the open field assay (Figure 1). Open field assays were introduced more than 80 years ago. It resembles a natural behavioral pattern and is one of the most widely used methods in animal behavioral research. Its popularity stems from the simplicity of the apparatus and clearly defined behaviors. Certain measurable motor behaviors are sensitive to a wide range of drugs and experimental manipulations and are sufficiently reliable under standardized conditions to give repeatable measures on an enormous range of independent variables. Simplicity, reproducibility (Figure 2), ease of quantification, and wide applicability are the prime determinants of its popularity. Open- field locomotor behaviors represent the interaction of the subject with the experimental situation. Most investigators study the effects of psychostimulants in open-field testing whether repetitive (chronic) drug exposure elicits behavioral tolerance or behavioral sensitization. Since drug liability is defined mainly on the basis of the subject behavioral response to drug exposure such as behavioral withdrawal, sensitization or tolerance. Behavioral expressions after psychostimulant administration develop gradually and progressively during the course of repeated exposure of psychostimulants, and this expression can persist for long periods of time after its discontinuation [14]. Thus, withdrawal, sensitization, and tolerance are considered a form of drug induced neuronal plasticity and are used as an experimental model and as a marker for drug effects, and for its liability for abuse.
In a dose response experiment using chronic 0.6, 2.5, and 10.0 mg/kg i.p. MPD, sometimes the groups (N=8) exhibited sensitization (Figure 3), sometimes expressed no effect of drug, and in few cases to 10.0 mg/kg MPD tolerance was observed [15,16]. This varied response forced us to increase the number of animals per group until a significant effect of the drug was obtained. Moreover, this observation suggests that the same dose of MPD can elicit behavioral tolerance in some animals and behavioral sensitization in others. To test this possibility, i.e. that the same repetitive (chronic) dose of MPD can elicit behavior sensitization in some animals and behavioral tolerance in others, the following experiment was conducted.
Methods
The experiment uses 166 adult (200-220 gr) male Sprague Dowley rats divided into 4 groups: 1) Saline (N=14); 2) 0.6 mg/kg MPD (N=47); 3) 2.5 mg/kg MPD (N=49) and group 4) 10.0 mg/kg (N=56). The experiment lasted for 10 consecutive days using the open field assay as follow. On experimental day 1 (ED1) saline was injected and behavioral recording were obtained for 60 min followed by either saline (the control group) or 0.6, 2.5, or 10.0 mg/kg MPD, and behavioral recordings were resumed for an additional 60 min. At ED2 to ED6, a single injection of either saline (the control group) or MPD at identical dose as on ED1 was given, followed by 3 washout days (ED7-ED9). At ED10 recording following saline and MPD resume identical to ED1 [8,9,11,12,16].
Activity obtained following MPD administration at ED1 compared to saline given at ED1 provide the acute effect of the drug, and activity following MPD at ED10 compared to activity at ED1 following MPD provide whether the drug elicits behavioral sensitization or tolerance.
To test this possibility, the data was evaluated as followed. All the animals for each dose were grouped into one, group #1, and statistically evaluated for whether the drug elicited behavioral sensitization or tolerance [10-12]. Each individual animal was statistically evaluated to determine whether behavioral sensitization or behavioral tolerance was expressed. Animals expressing behavioral sensitization were placed in group #2, and those expressing behavioral tolerance were summed into group #3.
Results
Figure 4 summarized the two locomotor indices of this experiment and shows that the same repetitive (chronic) dose of MPD elicits behavioral sensitization in some animals and behavioral tolerance in others (Figure 4).
Discussion
Several articles reported that healthy people deserve the right to boost their brains with psychoactive pills, like those prescribed for Attention Deficit Disorder (ADD), Attention Deficit Hyperactivity Disorder (ADHD), narcolepsy and memory- impaired older folks. College students are already taking MPD (Ritalin), mainly to help them study and to perform better during exams. Some students contend that: We should welcome new methods of improving our brain function and doing it with pills is no more morally objectionable than healthy eating, taking vitamins or getting a good night’s sleep with the help of a remedy. MPD is a psychoactive drug, but what do we know about this psychoactive drug? Psychoactive drug use dates back to prehistoric times: there is archaeological evidence for their use as much as several thousand years ago. A psychoactive drug acts in the central nervous system (CNS) to modulate consciousness, perception, mood and behavior. These drugs were used therapeutically as medication or for ritual and spiritual purposes, as well as recreationally to alter one’s mood and to get ‘high’. Because psychoactive drugs elicit changes in consciousness and mood, the user feels alert, joyful, pleasant, and becomes euphoric. Many psychoactive drugs are used and abused despite the risks of its consequences, such as dependence. MPD (Ritalin) belongs to this family of psychoactive drugs.
Psychostimulant medications such as amphetamine were used to treat attention deficit hyperactive disorder (ADHD) patients from 1930’s until it was found it elicits dependency. The psychostimulants methylphenidate (MPD) has since become the drug of choice to treat ADHD patients. MPD is a CNS stimulant that closely relates to the structure of dextroamphetamine, a derivative of amphetamine [6]. The neuropharmacological profile of MPD is also similar to that of cocaine [6]. The drug was first synthesized in 1944 and used initially as an analeptic for several types of barbiturate-induced comas. Since then, its usage has been extended to improve the alertness in children and adults with emotional, behavioral, and learning difficulties [17]. Treatment of children with MPD for extended periods of time when they are going through neurodevelopmental processes can modulate these critical neurodevelopmental processes that may alter the body’s homeostasis. Moreover, since chronic MPD use can elicit either behavioral withdrawal, sensitization, or tolerance [10-12,16], psychostimulant therapy given to adolescents and young adults may increase the risk for Substance Use Disorder. While, other reports suggest that psychostimulant treatment in adolescence for ADHD protects them from developing a future Substance Use Disorder. These contradictory reports call for basic in-depth studies to resolve this critical issue.
Conclusion
Behavioral sensitization and behavioral tolerance following the same chronic MPD dose of 0.6, 2.5, or 10.0 mg/kg exposure were observed. Expression of behavioral sensitization or tolerance following chronic psychostimulant exposure suggests that the drug has the potential to elicit dependence (addiction).
References

 

Figures at a glance

Figure Figure Figure Figure
Figure 1 Figure 2 Figure 3 Figure 4
Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Article Usage

  • Total views: 11713
  • [From(publication date):
    February-2015 - Nov 18, 2017]
  • Breakdown by view type
  • HTML page views : 7961
  • PDF downloads : 3752
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords